DB:PBD

Stock Analysis Report

Executive Summary

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally.

Rewards

Earnings are forecast to grow 36.42% per year

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€42M)



Snowflake Analysis

High growth potential with worrying balance sheet.


Similar Companies

Baxter International

NYSE:BAX

Share Price & News

How has Protalix BioTherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PBD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.0%

PBD

4.6%

DE Biotechs

1.0%

DE Market


1 Year Return

-29.2%

PBD

11.9%

DE Biotechs

15.7%

DE Market

Return vs Industry: PBD underperformed the German Biotechs industry which returned 11.9% over the past year.

Return vs Market: PBD underperformed the German Market which returned 15.7% over the past year.


Shareholder returns

PBDIndustryMarket
7 Day-11.0%4.6%1.0%
30 Day44.9%18.8%1.4%
90 Day24.5%9.2%6.7%
1 Year-29.2%-29.2%12.2%11.9%19.3%15.7%
3 Year-12.4%-12.4%79.8%77.7%19.5%8.9%
5 Year-85.7%-85.7%23.5%20.9%36.9%18.3%

Price Volatility Vs. Market

How volatile is Protalix BioTherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Protalix BioTherapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Protalix BioTherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalix BioTherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Protalix BioTherapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

36.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: PBD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PBD's is expected to become profitable in the next 3 years.

Revenue vs Market: PBD's revenue (23.1% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: PBD's revenue (23.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PBD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Protalix BioTherapeutics performed over the past 5 years?

-1.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PBD is currently unprofitable.

Growing Profit Margin: PBD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PBD is unprofitable, and losses have increased over the past 5 years at a rate of -1.6% per year.

Accelerating Growth: Unable to compare PBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PBD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: PBD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Protalix BioTherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PBD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PBD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PBD has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PBD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: PBD has a high level of physical assets or inventory.

Debt Coverage by Assets: PBD has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PBD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PBD has less than a year of cash runway if free cash flow continues to grow at historical rates of 54.1% each year.


Next Steps

Dividend

What is Protalix BioTherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PBD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PBD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PBD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PBD's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Protalix BioTherapeutics's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average management tenure


CEO

Dror Bashan 0

0.5yrs

Tenure

0

Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019, Mr. Bashan has over 20 years of experience in the pharmaceutical industry wit ...


Management Age and Tenure

5.3yrs

Average Tenure

57yo

Average Age

Experienced Management: PBD's management team is seasoned and experienced (5.3 years average tenure).


Board Age and Tenure

3.5yrs

Average Tenure

72yo

Average Age

Experienced Board: PBD's board of directors are considered experienced (3.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Management Team

  • Yoseph Shaaltiel (65yo)

    Founder and Executive VP Research & Development

    • Tenure: 13yrs
    • Compensation: US$433.44k
  • Eyal Rubin (44yo)

    SVP, CFO & Corporate Secretary

    • Tenure: 0.3yrs
  • Yaron Naos (55yo)

    Senior Vice President of Operations

    • Tenure: 1.6yrs
    • Compensation: US$339.27k
  • Einat Brill-Almon (59yo)

    Senior Vice President of Product Development

    • Tenure: 13yrs
    • Compensation: US$504.04k
  • Dafna Shelly

    Vice President of Human Resources

    • Tenure: 9.1yrs
  • Dror Bashan

    President

    • Tenure: 0.5yrs

Board Members

  • Amos Shalev (66yo)

    Independent Director

    • Tenure: 11.4yrs
    • Compensation: US$80.00k
  • Aharon Schwartz (76yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: US$65.56k
  • Charles Arntzen (78yo)

    Member of Scientific Advisory Board

    • Tenure: 3.5yrs
  • David Granot (72yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$19.76k
  • Alexander Levitzki (79yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • J. Ciechanover (72yo)

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Zeev Bronfeld (68yo)

    Independent Chairman

    • Tenure: 0.3yrs
    • Compensation: US$80.00k
  • Roger Kornberg (72yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$55.00k
  • Dror Bashan

    President

    • Tenure: 0.5yrs

Company Information

Protalix BioTherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Protalix BioTherapeutics, Inc.
  • Ticker: PBD
  • Exchange: DB
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$41.547m
  • Listing Market Cap: US$37.351m
  • Shares outstanding: 148.38m
  • Website: https://www.protalix.com

Number of Employees


Location

  • Protalix BioTherapeutics, Inc.
  • 2 Snunit Street
  • Science Park
  • Karmiel
  • 21000
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PLXAMEX (NYSE MKT LLC)YesOrdinary SharesUSUSDJan 2007
PBDDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2007
PLXTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSJan 2007

Biography

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression syste ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/15 21:07
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.